A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: effect on postoperative vigor and handgrip strength. Academic Article uri icon

Overview

abstract

  • This randomized trial assessed the effect of recombinant human erythropoietin (EPO) vs preoperative autologous donation (PAD) on postoperative vigor and handgrip strength in patients undergoing primary total joint arthroplasty. Adults with baseline hemoglobin level of 11 to 14 g/dL received EPO (600 IU/kg once weekly for 4 doses, n = 130) or PAD (n = 121) before primary, unilateral hip or knee arthroplasty. Mean changes in vigor score and handgrip strength from baseline were not significantly different between treatment groups. Multivariate analyses found a significant treatment effect favoring EPO over PAD for vigor, but not for handgrip strength. Patients in the EPO group had higher hemoglobin levels and required fewer transfusions. Both treatments were well tolerated. Additional study is needed to elucidate the influence of blood management strategies on postoperative vigor.

publication date

  • April 1, 2007

Research

keywords

  • Anemia
  • Arthroplasty, Replacement, Hip
  • Arthroplasty, Replacement, Knee
  • Blood Transfusion, Autologous
  • Erythropoietin
  • Hematinics

Identity

Scopus Document Identifier

  • 33947720037

Digital Object Identifier (DOI)

  • 10.1016/j.arth.2006.11.002

PubMed ID

  • 17400086

Additional Document Info

volume

  • 22

issue

  • 3